Page 8 - Dr Reddy's

Dr Reddy's Foundation launches new skill development initiative

Under the new model designed to be more impactful and self-sustainable, DRF has inaugurated 110 centres across the country

Dr Reddy's launches Nitroglycerin tablets in the US

A medicine that opens blood vessels to improve blood flow, used to treat patients complaining of chest pain among other symptoms

Dr Reddy's gets nod to export 15 drugs to EU

The order will enable the company to import these substances for a period of three years, ending June 2019

Dr Reddy's delivers a bitter pill

Higher competition led to poor performance even as three plants remained under the US FDA scanner

Dr Reddy's completes Rs 1,569.41 crore share buyback

In February this year, the company's board had approved a proposal to buyback shares

Growth challenges remain for Dr Reddy's

Acquisition of drug applications positive, but resolution of US regulatory issues holds key

Dr Reddy's buys 8 US drugs from Teva, Allergan for $350 million

The combined sales of the branded versions of the products in the US is about $3.5 bn

US Consumer Product Safety Commission seeks action against Dr Reddy's

Panel alleges drug maker failed to report a 'non-compliance, defect, unreasonable risk' relating to blister packs as is legally required

Dr Reddy's re-draws new drug plan

Unlike in the past, when it tried to produce its own molecule, this time the company is licensing these from abroad

Dr Reddy's launches psoriasis treatment spray

A prescription topical steroid approved by the USFDA in February, 2016

Dr Reddy's: Weak Q4, uncertainties remain

Venezuelan adjustments hit results. Plants under US scanner; slow India growth; hence, prospects subdued

Dr Reddy's Q4 net down 85% at Rs 75 cr

Provisioning to write down receivables from Venezuela, higher tax expenses and decrease in revenues impacted the company's profits

Dr Reddy's signs US licensing agreement with XenoPort

The drug major will pay an upfront fee of $50 million (Rs 335 crore) to XenoPort